Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to determine the effect of vedolizumab induction
treatment on clinical response and remission at 6 weeks and to determine the effect of
vedolizumab maintenance treatment on clinical remission at 52 weeks.